Last reviewed · How we verify
Antidepressant
At a glance
| Generic name | Antidepressant |
|---|---|
| Also known as | Fluoxetine, Duloxetine, Paroxetine, Escitalopram, Venlafaxine |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (PHASE3)
- Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder (NA)
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Pharmacogenetic-Guided Antidepressant Treatment in Depression (NA)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antidepressant CI brief — competitive landscape report
- Antidepressant updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI